Alyeska Investment Group
IMNM icon

Alyeska Investment Group’s Immunome IMNM Stock Holding History

Alyeska Investment Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-293,750
Closed -$6.31M – 676
2025
Q4 		$6.31M Buy
+293,750
New +$5.16M 0.02% 435

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Alyeska Investment Group's IMNM Position: Q1 2026 in Review

Alyeska Investment Group sold out of Immunome (IMNM) in Q1 2026, closing a stake of 293,750 shares — an estimated $6.31M sold.

Alyeska Investment Group first reported a position in IMNM in Q4 2025 and held it in 1 quarter. The position peaked at $6.31M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Alyeska Investment Group reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 293,750 Immunome shares in Q1 2026, an estimated $6.31M.
  • Alyeska Investment Group first reported a position in Immunome in Q4 2025 and held it in 1 quarter.
  • Alyeska Investment Group's Immunome position peaked at $6.31M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.